BACKGROUND: Myalgic encephalomyelitis (ME) and chronic fatigue syndrome (CFS) have case definitions with varying criteria, but almost all criteria require an individual to have a substantial reduction in activity level. Unfortunately, a consensus has not been reached regarding what constitutes substantial reductions. One measure that has been used to measure substantial reduction is the Medical Outcomes Study Short Form-36 Health Survey (SF-36).[1]. PURPOSE: The current study examined the relationship between the SF-36, a measure of current functioning, and a self-report measure of the percent reduction in hours spent on activities. RESULTS: Findings indicated that select subscales of the SF-36 accurately measure significant reductions in functioning. Further, this measure significantly differentiates patients from controls. CONCLUSION: Determining what constitutes a significant reduction in activity is difficult because it is subjective to the individual. However, certain subscales of the SF-36 could provide a uniform way to accurately measure and define substantial reductions in functioning.
BACKGROUND:Myalgic encephalomyelitis (ME) and chronic fatigue syndrome (CFS) have case definitions with varying criteria, but almost all criteria require an individual to have a substantial reduction in activity level. Unfortunately, a consensus has not been reached regarding what constitutes substantial reductions. One measure that has been used to measure substantial reduction is the Medical Outcomes Study Short Form-36 Health Survey (SF-36).[1]. PURPOSE: The current study examined the relationship between the SF-36, a measure of current functioning, and a self-report measure of the percent reduction in hours spent on activities. RESULTS: Findings indicated that select subscales of the SF-36 accurately measure significant reductions in functioning. Further, this measure significantly differentiates patients from controls. CONCLUSION: Determining what constitutes a significant reduction in activity is difficult because it is subjective to the individual. However, certain subscales of the SF-36 could provide a uniform way to accurately measure and define substantial reductions in functioning.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: L A Jason; J A Richman; A W Rademaker; K M Jordan; A V Plioplys; R R Taylor; W McCready; C F Huang; S Plioplys Journal: Arch Intern Med Date: 1999-10-11
Authors: Michele Reyes; Rosane Nisenbaum; David C Hoaglin; Elizabeth R Unger; Carol Emmons; Bonnie Randall; John A Stewart; Susan Abbey; James F Jones; Nelson Gantz; Sarah Minden; William C Reeves Journal: Arch Intern Med Date: 2003-07-14
Authors: B M Carruthers; M I van de Sande; K L De Meirleir; N G Klimas; G Broderick; T Mitchell; D Staines; A C P Powles; N Speight; R Vallings; L Bateman; B Baumgarten-Austrheim; D S Bell; N Carlo-Stella; J Chia; A Darragh; D Jo; D Lewis; A R Light; S Marshall-Gradisnik; I Mena; J A Mikovits; K Miwa; M Murovska; M L Pall; S Stevens Journal: J Intern Med Date: 2011-08-22 Impact factor: 8.989
Authors: William C Reeves; Dieter Wagner; Rosane Nisenbaum; James F Jones; Brian Gurbaxani; Laura Solomon; Dimitris A Papanicolaou; Elizabeth R Unger; Suzanne D Vernon; Christine Heim Journal: BMC Med Date: 2005-12-15 Impact factor: 8.775
Authors: Kristen D Gleason; Jamie Stoothoff; Damani McClellan; Stephanie McManimen; Taylor Thorpe; Ben Z Katz; Leonard A Jason Journal: Int J Behav Med Date: 2018-08
Authors: Trinitat Cambras; Jesús Castro-Marrero; Maria Cleofé Zaragoza; Antoni Díez-Noguera; José Alegre Journal: PLoS One Date: 2018-06-06 Impact factor: 3.240